Semax is a synthetic peptide developed in Russia that primarily boosts levels of brain-derived neurotrophic factor (BDNF), a protein essential for neuron survival, learning, and memory. It’s used clinically in Russia for stroke recovery and cognitive enhancement, though it remains unapproved by the FDA in the United States. Most people searching for Semax are curious about its nootropic potential, so here’s what the research actually shows.
How Semax Works in the Brain
Semax is a modified fragment of a natural hormone your body already produces (ACTH, which regulates your stress response). The modification makes it far more stable and longer-lasting. While the original hormone fragment breaks down in minutes, Semax has an action time of roughly 20 to 24 hours.
Its most well-documented effect is increasing the expression of BDNF, a growth factor that helps neurons survive, form new connections, and adapt. In animal studies, Semax boosted BDNF gene activity in the brain’s cortex within three hours of administration. It also ramped up nerve growth factor (NGF) expression at 24 and 72 hours, suggesting its neurotrophic effects unfold in waves over the first few days.
Beyond growth factors, Semax influences a surprisingly wide set of biological processes. Genome-wide analysis in rats found it altered the expression of genes related to immune cell activity, blood vessel formation, and calcium signaling in nerve tissue. Calcium acts as a messenger inside neurons, so changes in calcium regulation can affect how signals travel between brain cells. Semax also appears to inhibit nitric oxide synthesis and stabilize mitochondria (the energy-producing structures inside cells) under stress conditions.
Effects on Learning and Memory
Semax stimulates learning, attention, and memory formation in both animals and humans. In a 2025 study using a mouse model of Alzheimer’s disease, Semax improved performance across three standard cognitive tests. Mice given Semax showed greater interest in novel objects (a measure of recognition memory), navigated mazes more efficiently (spatial learning), and were generally more active and exploratory compared to untreated animals. The treated mice found escape locations faster and spent less time searching, indicating better memory retention.
These results come from disease models rather than healthy populations, which is an important distinction. The proposed mechanism is straightforward: by increasing BDNF and related growth factors, Semax supports the synaptic plasticity that underlies learning. Whether these effects translate to meaningful cognitive gains in healthy humans remains less well-documented in published research.
Stroke Recovery
The strongest clinical evidence for Semax comes from stroke treatment. In a study of 110 ischemic stroke patients, those who received Semax (administered intranasally at 6,000 micrograms per day for two 10-day courses) showed faster functional recovery and improved motor performance. The improvements correlated with higher BDNF levels in blood plasma, and patients who began rehabilitation early alongside Semax treatment saw the best outcomes on the Barthel index, a standard measure of daily functioning after stroke.
At the cellular level, Semax promotes neuron survival during oxygen deprivation and protects against glutamate toxicity, the chemical cascade that kills brain cells during a stroke. Within hours of a stroke, Semax activates genes involved in cell proliferation, migration, and immune response in damaged brain tissue. It also influences blood vessel-related genes involved in the growth of new vessels and the migration of the cells that line them, which matters for restoring blood flow to injured areas.
Potential for ADHD
Researchers have proposed Semax as a candidate for treating ADHD based on two key properties: it can amplify the effects of stimulants on dopamine release in the brain, and it boosts BDNF synthesis. Since ADHD is considered a neurodevelopmental condition involving disrupted dopamine and BDNF function, the theoretical fit is reasonable. Semax has also been shown to improve selective attention and influence brain development in animal studies. However, this remains a hypothesis supported by animal data and mechanistic reasoning, not large-scale human trials.
How It’s Taken and How Quickly It Works
Semax is administered as a nasal spray. When delivered intranasally in rats, detectable amounts reach the brain within two minutes. The concentration of intact Semax in brain tissue is 10 to 15 times higher after nasal delivery compared to injection into the bloodstream, which is why the intranasal route is preferred. The peptide breaks down rapidly through enzymatic digestion, with most of the compound cleared from the brain and blood within the first 15 minutes. Despite this quick breakdown, its biological effects persist for 20 to 24 hours, likely because the downstream changes it triggers (gene expression, growth factor production) continue long after the peptide itself is gone.
Safety and Side Effects
Published research on Semax reports relatively few adverse effects, but this reflects a limited body of clinical data rather than confirmed long-term safety. The FDA has flagged Semax as a compounding substance that may present significant safety risks, specifically citing the potential for immune reactions (immunogenicity) due to peptide aggregation and impurities. The agency’s position is that it lacks sufficient safety information to determine whether the drug causes harm in humans at the routes of administration people typically use.
One concern worth noting: Semax substantially alters immune gene expression, particularly genes encoding immunoglobulins and chemokines. Within 24 hours of administration in animal models, its effects on the immune system increased considerably compared to the three-hour mark. For most users this may be inconsequential, but the long-term implications of repeatedly modulating immune gene activity are not well characterized.
Regulatory Status
Semax is approved and prescribed in Russia for conditions including stroke, cognitive disorders, and optic nerve disease. It is not approved by the FDA for any indication in the United States. The FDA lists it among bulk drug substances used in compounding that may present safety risks, effectively discouraging its inclusion in compounded medications. It is not a controlled substance, but its availability in the U.S. exists in a gray area, primarily through research chemical suppliers and peptide vendors rather than pharmacies.